Nucor earnings beat by $0.08, revenue fell short of estimates
Pluri Inc. (NASDAQ:PLUR), a small-cap biological products company with a market capitalization of $36 million, has announced that its 2025 Annual Meeting of Shareholders will take place on May 23, 2025, at 5:00 p.m. Israel time. According to InvestingPro data, the company’s stock has gained over 12% year-to-date despite challenging market conditions. This event will be held at the company’s headquarters in the MATAM Advanced Technology Park, Haifa, Israel.
The date of the upcoming annual meeting represents a shift of over 30 days from the previous year’s meeting. In preparation for the meeting, the company has established March 24, 2025, as the record date for shareholders eligible to receive notice and vote. The meeting comes shortly after the company’s Q1 earnings report, scheduled for May 9, 2025, which analysts will watch closely as they expect improved financial performance this year.
Shareholders interested in submitting proposals for the meeting had a deadline of January 2, 2025. Proposals submitted by this date will be considered for inclusion in the proxy materials. This deadline was determined in accordance with the SEC’s Rule 14a-5(f) and Rule 14a-8(e), ensuring the company has adequate time to incorporate the proposals into its proxy materials.
The January 2 deadline also serves to determine the timeliness of shareholder proposals for discretionary voting by proxies under Rule 14a-4(c)(1) and to meet the notice requirements of Rule 14a-19.
This announcement is based on a press release statement and follows the regulatory guidelines set by the Securities and Exchange Commission.
In other recent news, Pluri Inc. has completed the acquisition of a majority stake in Kokomodo Ltd., purchasing approximately 71% of its equity for $4.5 million. This acquisition is part of Pluri’s expansion strategy, aimed at enhancing its product offerings and market reach. Additionally, Pluri Inc. has amended its Securities Purchase Agreement with an investor group led by board director Alejandro Weinstein, facilitating the exchange of common shares for pre-funded warrants. These warrants are exercisable pending shareholder approvals and come with anti-dilution protections.
In a setback, Pluri’s subsidiary, Pluri Biotech Ltd., received a contract termination notice from the U.S. National Institute of Allergy and Infectious Diseases, ending a $4.2 million contract for the development of the PLX-R18 cell therapy. On a more positive note, Pluri has secured new U.S. and Israeli patents for its immune cell expansion technologies, focusing on methods for culturing immune cells using proprietary 3D cell expansion bioreactors. These advancements aim to provide scalable solutions for cancer treatment.
Pluri Inc. has also announced its 2025 Annual Meeting of Shareholders will be held on May 14, 2025, in Haifa, Israel. This announcement underscores the company’s adherence to corporate governance practices and regulatory requirements. These developments highlight Pluri’s ongoing strategic initiatives and challenges within the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.